PHARMING GROUP NV (PHARM.AS) Stock Price, Forecast & Analysis
AMS:PHARM • NL0010391025
PHARM.AS Key Statistics, Chart & Performance
The current stock price of PHARM.AS is 1.331 EUR. In the past month the price decreased by -16.71%. In the past year, price increased by 55.76%.
PHARM.AS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PHARM.AS. When comparing the yearly performance of all stocks, PHARM.AS is one of the better performing stocks in the market, outperforming 85.61% of all stocks.
PHARM.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS. PHARM.AS has an average financial health and profitability rating.
PHARM.AS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.11% | ||
| ROA | 0.08% | ||
| ROE | 0.14% | ||
| Debt/Equity | 0.46 |
PHARM.AS Forecast & Estimates
14 analysts have analysed PHARM.AS and the average price target is 2.19 EUR. This implies a price increase of 64.76% is expected in the next year compared to the current price of 1.331.
For the next year, analysts expect an EPS growth of 111.44% and a revenue growth 26.31% for PHARM.AS
PHARM.AS Ownership
PHARM.AS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.11 | 43.863B | ||
| 1AE | ARGENX SE | 27.99 | 43.776B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.617B | ||
| ABVX | ABIVAX SA | N/A | 8.158B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.882B | ||
| GLPG | GALAPAGOS NV | N/A | 1.869B | ||
| IVA | INVENTIVA SA | N/A | 1.092B | ||
| 6IV | INVENTIVA SA | N/A | 1.034B | ||
| NANO | NANOBIOTIX | N/A | 1.006B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Amsterdam Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About PHARM.AS
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 404
Phone: 31715247400
PHARMING GROUP NV / PHARM.AS FAQ
What does PHARMING GROUP NV do?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
What is the current price of PHARM stock?
The current stock price of PHARM.AS is 1.331 EUR. The price increased by 2.38% in the last trading session.
What is the dividend status of PHARMING GROUP NV?
PHARM.AS does not pay a dividend.
How is the ChartMill rating for PHARMING GROUP NV?
PHARM.AS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of PHARM stock?
PHARMING GROUP NV (PHARM.AS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for PHARMING GROUP NV?
The Revenue of PHARMING GROUP NV (PHARM.AS) is expected to grow by 26.31% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does PHARMING GROUP NV (PHARM.AS) report earnings?
PHARMING GROUP NV (PHARM.AS) will report earnings on 2026-03-12, after the market close.